|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E) mutation is identified in a subset of cutaneous metastases from PTC.
|
17387744 |
2007 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Together, these results suggest that targeting mutant (V600E)B-Raf reduces melanoma cell extravasation by decreasing IL-8 production and interrupting ICAM-1-beta2 integrin binding of melanoma cells to the endothelium mediated by PMNs in the microcirculation, which provides a rationale and mechanistic basis for targeting mutant (V600E)B-Raf to inhibit melanoma extravasation and subsequent metastasis development.
|
17575149 |
2007 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Together, these results suggest that targeting mutant (V600E)B-Raf reduces melanoma cell extravasation by decreasing IL-8 production and interrupting ICAM-1-beta2 integrin binding of melanoma cells to the endothelium mediated by PMNs in the microcirculation, which provides a rationale and mechanistic basis for targeting mutant (V600E)B-Raf to inhibit melanoma extravasation and subsequent metastasis development.
|
17575149 |
2007 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The BRAF(V600E) mutation was detected in 88 of the tumors examined, with significant differences between groups with and without lymph node (LN) metastases; the mean age of patients with BRAF(V600E) mutation was significantly higher than that of patients without mutations.
|
17685465 |
2007 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The BRAF(V600E) mutation was detected in 88 of the tumors examined, with significant differences between groups with and without lymph node (LN) metastases; the mean age of patients with BRAF(V600E) mutation was significantly higher than that of patients without mutations.
|
17685465 |
2007 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In patients with conventional papillary thyroid cancer, BRAF V600E mutation was associated with older age (P = 0.0381), lymph node metastasis (P = 0.0323), distant metastasis (P = 0.045), higher TNM stage (I and II vs. III and IV, P = 0.0389), and recurrent and persistent disease (P = 0.009) with a median follow-up time of 6.0 years.
|
17717450 |
2007 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In patients with conventional papillary thyroid cancer, BRAF V600E mutation was associated with older age (P = 0.0381), lymph node metastasis (P = 0.0323), distant metastasis (P = 0.045), higher TNM stage (I and II vs. III and IV, P = 0.0389), and recurrent and persistent disease (P = 0.009) with a median follow-up time of 6.0 years.
|
17717450 |
2007 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E was associated with extrathyroidal invasion (P < 0.0001), multicentricity (P = 0.0026), presence of nodal metastases (P = 0.0009), class III vs. classes I and II (P < 0.00000006), and absence of tumor capsule (P < 0.0001), in particular in follicular- and micro-PTC variants.
|
17785355 |
2007 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E was associated with extrathyroidal invasion (P < 0.0001), multicentricity (P = 0.0026), presence of nodal metastases (P = 0.0009), class III vs. classes I and II (P < 0.00000006), and absence of tumor capsule (P < 0.0001), in particular in follicular- and micro-PTC variants.
|
17785355 |
2007 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this study, the BRAF (V600E) mutation in 54 PTCs was investigated and the relationship between the BRAF mutation and clinicopathological features such as age, gender, tumor size, extrathyroid extension, lymph node metastasis, and distant metastasis was analyzed.
|
17972530 |
2007 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this study, the BRAF (V600E) mutation in 54 PTCs was investigated and the relationship between the BRAF mutation and clinicopathological features such as age, gender, tumor size, extrathyroid extension, lymph node metastasis, and distant metastasis was analyzed.
|
17972530 |
2007 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Univariate analysis indicated that BRAF((V600E)) was associated with greater tumor size (P=0.0048), extra-thyroid invasion (P<0.0001), and cervical lymph nodal metastases (P=0.0001).
|
18310287 |
2008 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Univariate analysis indicated that BRAF((V600E)) was associated with greater tumor size (P=0.0048), extra-thyroid invasion (P<0.0001), and cervical lymph nodal metastases (P=0.0001).
|
18310287 |
2008 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
At univariate analysis the worst outcome for PTC patients was significantly correlated with clinicopathological features (i.e. age, tumor size, extrathyroid extension, lymph node and distant metastases, advanced stage, vascular endothelial growth factor expression, and vascular invasion) and the BRAF(V600E) mutation (P < 0.002).
|
18682506 |
2008 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
At univariate analysis the worst outcome for PTC patients was significantly correlated with clinicopathological features (i.e. age, tumor size, extrathyroid extension, lymph node and distant metastases, advanced stage, vascular endothelial growth factor expression, and vascular invasion) and the BRAF(V600E) mutation (P < 0.002).
|
18682506 |
2008 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The prevalence of BRAF(V600E) mutation of PTMCs with high aggressiveness (advanced disease stages, extrathyroidal extension, and nodal metastasis) was significantly higher (p < 0.05) than that of PTMCs without aggressive behavior.
|
19034577 |
2009 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The prevalence of BRAF(V600E) mutation of PTMCs with high aggressiveness (advanced disease stages, extrathyroidal extension, and nodal metastasis) was significantly higher (p < 0.05) than that of PTMCs without aggressive behavior.
|
19034577 |
2009 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(T1799A) can be detected in the blood of PTC patients with residual or metastatic disease and may provide diagnostic information.
|
19850689 |
2009 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The activating mutation BRAF(V600E) is a frequent genetic event in papillary thyroid carcinomas (PTC) that predicts a poor prognosis, leading to loss of sodium/iodide symporter (NIS) expression and subsequent radioiodide-refractory metastatic disease.
|
19861538 |
2009 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The activating mutation BRAF(V600E) is a frequent genetic event in papillary thyroid carcinomas (PTC) that predicts a poor prognosis, leading to loss of sodium/iodide symporter (NIS) expression and subsequent radioiodide-refractory metastatic disease.
|
19861538 |
2009 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, B-Raf(V600E) plays an important role in PTC progression through genes (i.e., TSP-1) important in tumor invasion and metastasis.
|
20498063 |
2010 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, B-Raf(V600E) plays an important role in PTC progression through genes (i.e., TSP-1) important in tumor invasion and metastasis.
|
20498063 |
2010 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We therefore analyzed the correlation of BRAF V600E and ERK-activation in 20 malignant melanomas and 21 subsequently evolved, paired metastases of the same donor by BRAF exon 15 DNA sequencing and phospho-specific immunohistochemistry for ERK.
|
20605766 |
2010 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We therefore analyzed the correlation of BRAF V600E and ERK-activation in 20 malignant melanomas and 21 subsequently evolved, paired metastases of the same donor by BRAF exon 15 DNA sequencing and phospho-specific immunohistochemistry for ERK.
|
20605766 |
2010 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Patients with BRAF(V600E) wild-type primary tumor do not appear to acquire the mutation in their metastases, and BRAF(V600E) is associated with poorer outcomes in metastatic patients.
|
20635392 |
2011 |